TrialSignal
Clinical trial intelligence report
A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04454398
Status
WITHDRAWN
Phase
PHASE1
Sponsor
Sorrento Therapeutics, Inc.
Executive brief
Investment-Ready Snapshot
Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04454398
Indication
Covid-19
Modality
monoclonal antibody
Target
COVI-GUARD, Standard of Care, Placebo
Intervention
COVI-GUARD, Standard of Care, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.